financetom
Business
financetom
/
Business
/
TransDigm Fiscal Q3 Adjusted Earnings, Sales Rise; Full-Year Outlook Revised -- Shares Down Pre-Bell
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
TransDigm Fiscal Q3 Adjusted Earnings, Sales Rise; Full-Year Outlook Revised -- Shares Down Pre-Bell
Aug 5, 2025 4:52 AM

07:37 AM EDT, 08/05/2025 (MT Newswires) -- TransDigm Group ( TDG ) reported fiscal Q3 adjusted earnings Tuesday of $9.60 per diluted share, up from $9 a year earlier.

Analysts polled by FactSet expected $9.89.

Net sales for the quarter ended June 28 were $2.24 billion, compared with $2.05 billion a year earlier.

Analysts polled by FactSet expected $2.3 billion.

The company said it now expects fiscal 2025 adjusted EPS of $36.33 to $37.15 on sales of $8.76 billion to $8.82 billion. TransDigm ( TDG ) previously projected adjusted EPS at $35.51 to $37.43 on sales of $8.75 billion to $8.95 billion.

Analysts are looking for $37.48 and $8.88 billion, respectively.

The company's shares were down 7.4% in recent premarket activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Tempest Therapeutics to Advance Liver Cancer Drug to Phase 3 Trial with Roche; Shares Jump Pre-Bell
Tempest Therapeutics to Advance Liver Cancer Drug to Phase 3 Trial with Roche; Shares Jump Pre-Bell
Oct 10, 2024
07:56 AM EDT, 10/10/2024 (MT Newswires) -- Tempest Therapeutics ( TPST ) said Thursday it is working with Roche to advance amezalpat into a phase 3 trial in combination with atezolizumab and bavacizumab for the first-line treatment of unresectable or metastatic hepatocellular carcinoma. As part of the agreement, Roche will provide atezolizumab worldwide, while Tempest will sponsor and lead the...
Immatics Launches $150 Million Public Offering of Ordinary Shares
Immatics Launches $150 Million Public Offering of Ordinary Shares
Oct 10, 2024
07:58 AM EDT, 10/10/2024 (MT Newswires) -- Immatics ( IMTX ) said Thursday that it has launched a $150 million underwritten public offering of its ordinary shares. The company said there is no guarantee as to when or if the offering will be completed, or as to the actual size and terms of the offering, as these are contingent on...
--GXO Logistics Shares Rise Pre-Bell After Bloomberg Reports Company Exploring Sale
--GXO Logistics Shares Rise Pre-Bell After Bloomberg Reports Company Exploring Sale
Oct 10, 2024
07:58 AM EDT, 10/10/2024 (MT Newswires) -- Price: 56.06, Change: +5.16, Percent Change: +10.14 ...
US Senator Warren calls for scrutiny of Novo Holdings' Catalent deal
US Senator Warren calls for scrutiny of Novo Holdings' Catalent deal
Oct 10, 2024
NEW YORK, Oct 10 (Reuters) - U.S. Senator Elizabeth Warren has asked antitrust regulators to closely scrutinize a $16.5 billion deal in which Novo Nordisk's controlling shareholder would acquire contract drug manufacturer Catalent ( CTLT ), saying it may give the pharmaceutical company an unlawful advantage in weight loss and obesity drugs. Novo Holdings, the investment firm that has a...
Copyright 2023-2026 - www.financetom.com All Rights Reserved